Reach Us +1-217-403-9671
Managing US Food And Drug Administration Inspections At Indian Clinical Trial Sites- CRO Perspective | 7408
ISSN: 2167-7689

Pharmaceutical Regulatory Affairs: Open Access
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Managing US Food and Drug Administration inspections at Indian clinical trial sites- CRO perspective

2nd International Conference and Exhibition on Pharmaceutical Regulatory Affairs

Ashutosh Jani

ScientificTracks Abstracts: Pharmaceut Reg Affairs

DOI: 10.4172/2167-7689.S1.002

The U.S. Food and Drug Administration (FDA) conduct clinical site inspections under what is known as the Bioresearch Monitoring Program. The agency now conducts several hundred inspections of clinical investigators annually to obtain compliance with the regulations and to ensure that data submitted to the FDA are substantiated by appropriate records. The Inspection is simply a quality assurance process used to verify clinical data and regulatory compliance. However it can still be an unnerving experience, particularly if you are not prepared. Its important to know who gets Inspected? It may be because of High enrollment at sites, suspected data (no AEs, too many AEs and data not trending like other sites), large number of deviations, complaints against site etc. Data auditing and validate the data from the study is a Primary focus of FDA inspectors during the GCP BIMO inspections conducted at clinical investigator sites it helps to confirm credibility of data. The FDA inspectors verify the site delegations, study conduct and most importantly the documentation. Indian sites are not used to any audits or inspections of their medical practice or clinical research from any agency. Hence, they underestimate the importance of FDA inspection. It could result into a casual attitude to inspection. The Principle Investigator needs to devote 4--5 days time required for the inspection. The seriousness of the regulatory inspection should be percolated into every staff member of the institute. It requires a lot of planning from the team. The FDA inspection should not to be left to CRA and QA personnel. There should be a strong Management oversight. The investigator and his team should be appraised about the deficiencies in the conduct of trial and the site documentation, and advised about how to respond to FDA inspector's inquiries and findings, by training them in dos and don'ts for the interview and the inspection process.
Ashutosh Jani has completed his Ph.D from L. M College of Pharmacy, Gujarat University. He is the Head of Clinical Trials at Accutest Research Laboratory, Ahmedabad, a premier Independent Contract Research organization in India. He has published more than 10 papers in reputed journals and serving as an editorial board member of reputed journals.